BCL9 and CTNNB1 |
B-cell CLL/lymphoma 9 |
catenin (cadherin-associated protein), beta 1, 88kDa |
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
CTNNB1 and NFKB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
CTNNB1 and PTPRU |
catenin (cadherin-associated protein), beta 1, 88kDa |
protein tyrosine phosphatase, receptor type, U |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
|
CTNNB1 and CTNNA3 |
catenin (cadherin-associated protein), beta 1, 88kDa |
catenin (cadherin-associated protein), alpha 3 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
|
ITIH4 and TP63 |
inter-alpha-trypsin inhibitor heavy chain family, member 4 |
tumor protein p63 |
|
|
|
|
|
|
BAG6 and TP63 |
BCL2-associated athanogene 6 |
tumor protein p63 |
|
|
|
|
|
|
HLA-DQA1 and IKBKG |
major histocompatibility complex, class II, DQ alpha 1 |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- IRAK1 recruits IKK complex
- Downstream signaling events of B Cell Receptor (BCR)
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- NOD1/2 Signaling Pathway
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- IRAK1 recruits IKK complex
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Innate Immune System
- activated TAK1 mediates p38 MAPK activation
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- IKK complex recruitment mediated by RIP1
- Cytosolic sensors of pathogen-associated DNA
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by Interleukins
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Activation of NF-kappaB in B cells
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Adaptive Immune System
|
|
|
|
|
APC and SYNE1 |
adenomatous polyposis coli |
spectrin repeat containing, nuclear envelope 1 |
- misspliced GSK3beta mutants stabilize beta-catenin
- APC truncation mutants have impaired AXIN binding
- T41 mutants of beta-catenin aren't phosphorylated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Programmed Cell Death
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Apoptotic cleavage of cellular proteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Apoptotic execution phase
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
|
APLP1 and HLA-DQA1 |
amyloid beta (A4) precursor-like protein 1 |
major histocompatibility complex, class II, DQ alpha 1 |
|
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
CD74 and HLA-DQA1 |
CD74 molecule, major histocompatibility complex, class II invariant chain |
major histocompatibility complex, class II, DQ alpha 1 |
- MHC class II antigen presentation
- Adaptive Immune System
|
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
CDK7 and HLA-DQA1 |
cyclin-dependent kinase 7 |
major histocompatibility complex, class II, DQ alpha 1 |
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Tat-mediated elongation of the HIV-1 transcript
- Cyclin E associated events during G1/S transition
- Formation of transcription-coupled NER (TC-NER) repair complex
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- G1/S Transition
- Mitotic G1-G1/S phases
- S Phase
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Cyclin A:Cdk2-associated events at S phase entry
- Mitotic G2-G2/M phases
- Transcription of the HIV genome
- Nucleotide Excision Repair
- RNA Polymerase II Transcription
- RNA Polymerase I Transcription Initiation
- HIV Infection
- RNA Polymerase I Promoter Clearance
- Formation of the Early Elongation Complex
- G2/M Transition
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- Cyclin A/B1 associated events during G2/M transition
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- RNA Polymerase I Transcription
- mRNA Capping
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- G1 Phase
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Cell Cycle, Mitotic
- Cyclin D associated events in G1
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Elongation
|
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Phosphonothreonine
- Flavopiridol
|
|
|
|
HLA-DQA1 and UNC119 |
major histocompatibility complex, class II, DQ alpha 1 |
unc-119 homolog (C. elegans) |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
|
HLA-DQA1 and LRIF1 |
major histocompatibility complex, class II, DQ alpha 1 |
ligand dependent nuclear receptor interacting factor 1 |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
|
HLA-DQA1 and TLE1 |
major histocompatibility complex, class II, DQ alpha 1 |
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- truncations of AMER1 destabilize the destruction complex
- FBXW7 Mutants and NOTCH1 in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- NOTCH1 Intracellular Domain Regulates Transcription
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by WNT in cancer
|
|
|
|
|
HLA-DQA1 and SH3GL2 |
major histocompatibility complex, class II, DQ alpha 1 |
SH3-domain GRB2-like 2 |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Retrograde neurotrophin signalling
- EGFR downregulation
- Signalling by NGF
- Axon guidance
- Golgi Associated Vesicle Biogenesis
- L1CAM interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- Clathrin derived vesicle budding
- Lysosome Vesicle Biogenesis
- Signaling by EGFR
- MHC class II antigen presentation
- Signaling by EGFR in Cancer
- trans-Golgi Network Vesicle Budding
- Adaptive Immune System
|
|
|
|
|
MDM2 and SMARCA2 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
- Chromatin modifying enzymes
- Chromatin organization
- RMTs methylate histone arginines
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
|
FLNA and KCNJ2 |
filamin A, alpha |
potassium channel, inwardly rectifying subfamily J, member 2 |
- Cell junction organization
- GP1b-IX-V activation signalling
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Cell-extracellular matrix interactions
|
- GABA B receptor activation
- Inwardly rectifying K+ channels
- GABA receptor activation
- Activation of G protein gated Potassium channels
- Classical Kir channels
- Activation of GABAB receptors
- Potassium Channels
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- G protein gated Potassium channels
- Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
- Transmission across Chemical Synapses
|
|
|
|
|
KCNJ2 and KCNJ11 |
potassium channel, inwardly rectifying subfamily J, member 2 |
potassium channel, inwardly rectifying subfamily J, member 11 |
- GABA B receptor activation
- Inwardly rectifying K+ channels
- GABA receptor activation
- Activation of G protein gated Potassium channels
- Classical Kir channels
- Activation of GABAB receptors
- Potassium Channels
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- G protein gated Potassium channels
- Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
- Transmission across Chemical Synapses
|
- Inwardly rectifying K+ channels
- Integration of energy metabolism
- ATP sensitive Potassium channels
- Regulation of insulin secretion
- Potassium Channels
|
|
- Glimepiride
- Ibutilide
- Verapamil
- Levosimendan
- Glyburide
- Diazoxide
- Thiamylal
|
|
|
AR and HDAC4 |
androgen receptor |
histone deacetylase 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and TCF4 |
androgen receptor |
transcription factor 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- CDO in myogenesis
- Myogenesis
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|